MIP Pharma Lietuva - Company finances
|
EUR
|
2018
From: 2017-07-01
To: 2018-06-30
|
2019
From: 2018-07-01
To: 2019-06-30
|
2020
From: 2019-07-01
To: 2020-06-30
|
2021
From: 2020-07-01
To: 2021-06-30
|
2022
From: 2021-07-01
To: 2022-06-30
|
2023
From: 2022-07-01
To: 2023-06-30
|
2024
From: 2023-07-01
To: 2024-06-30
|
2025
From: 2024-07-01
To: 2025-06-30
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 166,585 | 13,647 | 113,399 | 15,893 | 100,994 | 30,931 | 38,176 | 30,055 |
| Profit before tax | 108,557 | -41,428 | 59,576 | -40,502 | 79,371 | 20,251 | 29,607 | 18,148 |
| Net profit | 103,672 | -41,428 | 56,891 | -40,502 | 73,548 | 19,340 | 28,275 | 15,809 |
| Equity | 36,792 | -4,636 | 52,255 | 11,752 | 85,300 | 104,641 | 132,916 | 148,725 |
| Liabilities | 7,526 | 11,996 | 3,442 | 637 | 6,450 | 1,558 | 6,326 | 21,076 |
| Non-current assets | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Current assets | 44,131 | 7,815 | 56,163 | 13,028 | 92,390 | 106,839 | 139,882 | 170,441 |
| Total assets | 44,132 | 7,816 | 56,164 | 13,029 | 92,390 | 106,839 | 139,882 | 170,441 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +93.9% | -91.8% | +730.9% | -86.0% | +535.5% | -69.4% | +23.4% | -21.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 234.9% | -530.0% | 101.3% | -310.9% | 79.6% | 18.1% | 20.2% | 9.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 281.8% | - | 108.9% | -344.6% | 86.2% | 18.5% | 21.3% | 10.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 62.2% | -303.6% | 50.2% | -254.8% | 72.8% | 62.5% | 74.1% | 52.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 65.2% | -303.6% | 52.5% | -254.8% | 78.6% | 65.5% | 77.6% | 60.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.2 | - | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 83,293 | 6,824 | 56,700 | 10,595 | 100,994 | 30,931 | 38,176 | 30,055 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
MIP Pharma Lietuva - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-10-16 | 2025-10-16 | 215.77 |
| 2025-07-16 | 2025-08-12 | 0.01 |
| 2024-11-18 | 2024-11-18 | 196.52 |
MIP Pharma Lietuva - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
MIP Pharma Lietuva, UAB (code 302508947) is a Private Limited Liability Company active in the wholesale of pharmaceutical and medical goods. In 2025, revenue amounted to €30.1K, which was 21.3% lower year on year and 2.8% below the 2023 level. Net profit was €15.8K, compared with €28.3K in 2024 and €19.3K in 2023, indicating that the company remained profitable despite a weaker top line in the latest year. The 2025 profit margin was 52.6%, below the exceptionally strong 2024 level of 74.1% but still high. The balance sheet expanded over the period: total assets reached €170.4K in 2025, up from €139.9K in 2024 and €106.8K in 2023. Equity increased to €148.7K, while liabilities rose to €21.1K from €6.3K a year earlier. Key ratios for 2025 show a solid capital structure, with an equity ratio of 87.3% and debt-to-equity of 0.14. ROE was 10.6%, ROA 9.3%, and asset turnover 0.18x. Revenue per employee was €30.1K and profit per employee €15.8K.